Aging is the major risk factor for the development of human neurodegenerative maladies such as Alzheimer's, Huntington's and Parkinson's diseases (PDs) and prion disorders, all of which stem from toxic protein aggregation. All of these diseases are correlated with cognitive decline. Cognitive Decline is a dynamic state from normal cognition of aging to dementia. According to the original criteria for Alzheimer's Disease (AD) (1984), a clinical diagnosis was possible only when someone was already demented. The prevalence rates of Cognitive Decline (mild cognitive impairment plus dementia) are very high now and will be higher in future because of the increasing survival time of people. Many neurological and psychiatric diseases are correlated with cognitive decline. Diagnosis of cognitive decline is mostly clinical (clinical criteria), but there are multiple biomarkers that could help us mostly in research programs such as short or long, paper and pencil or computerized neuropsychological batteries for cognition, activities of daily living and behavior, electroencephalograph, event-related potentials, and imaging-structural magnetic resonance imaging (MRI) and functional (fMRI, Pittsburgh bound positron emission tomography, FDG-PET, single photon emission computerized tomography and imaging of tau pathology)-cerebrospinal fluid proteins (Abeta, tau and phospho-tau in AD and α-synuclein (αSyn) for PD). Blood biomarkers need more studies to confirm their usefulness. Genetic markers are also studied but until now are not used in clinical praxis. Finally, in everyday clinical praxis and in research workout for early detection of cognitive decline, the combination of biomarkers is useful.
DEFINITIONS AND CRITERIA
Cognitive Decline is a dynamic state from normal cognition to dementia, where interventions can be taken to stop or delay the progression to dementia. At early stages, it is broadly of two types-amnestic, where memory loss is the chief concern, and non-amnestic, where it is not. One variant of non-amnestic, dysexecutive, which is more prevalent, is sometimes known as a separate subtype by itself. The term dementia refers to an acquired deficit of cognitive function(s), which may include complex attention, executive ability, learning and memory, language, visuospatial-perceptual ability praxis and social cognition. The cognitive deficits may or may not be accompanied by behavioral disorders and must be sufficient to interfere with functional independence. The clinical diagnosis of the dementia syndrome should rely on the DSM-IV TR (APA, 2000) or ICD-10 criteria (2007). In the development of DSM-5, the term 'dementia' is replaced by major or minor neurocognitive disorder (www. dsm5.org). 1 Alzheimer's Association and the National Institute on Aging have developed a new classification scheme that has categorized Alzheimer's Disease (AD) into a preclinical phase (research category), mild cognitive impairment (MCI) due to AD, and dementia of Alzheimer's type. 2 There are differences in approach, terminology, and use of cognitive markers and biomarkers. Validation and likely also modification are needed before they can be applied in clinical practice.
EPIDEMIOLOGY
The prevalence rate of MCI in Greece is 25.9% 3 among the elderly older than 65 years. The incidence rates for MCI are high, particularly among men and for single-domain MCI; the incidence of MCI was 104.6 (95% confidence interval: 81.6-127.7) per 1000 person-years, with higher incidence in men (men, 156.8; women, 70.3) in Australia. Rates for amnestic and non-amnestic MCI were comparable. Multidomain amnestic MCI was the most likely subtype to progress to dementia, but overall, the diagnosis of MCI, particularly singledomain MCI, shows considerable instability. 4 Dementia affects 5.4% of people over 65 years, and its prevalence increases further with age. The number of people affected will double every 20 years to 135 million by 2050, according to the Alzheimer Disease International World Alzheimer Report 2013. 5 In the EU, 4160 million people are aged over 60 years, the crude estimate prevalence of dementia is 6.2% and almost 9.95 million have a form of dementia. Almost 14 million Europeans are expected to have dementia by 2030. 1 
PARKINSON DISEASE DEMENTIA (PDD)
Approximately one-third of patients with newly diagnosed PD fulfill the consensus criteria for PD-MCI; after 5 years, this proportion is approximately 50% of patients without dementia. 7 The suggested clinical diagnostic criteria for PDD involve some domains that are anchored in core features, associated clinical features, features that make the diagnosis uncertain and features that are not compatible with the diagnosis of PDD (impairment in attention, memory, executive and visuospatial functions, and behavioral symptoms such as affective changes, hallucinations and apathy are frequent). When all criteria are satisfactorily met, probable PDD is designated; when clinical characteristics are atypical or uncertainty factors exist, possible PDD is designated. 1 
LEWY BODY DISEASE
Dementia with Lewy bodies is the second most common type of degenerative dementia, accounting for 10-15% of cases, and it represents one part of a spectrum of neurodegenerative disorders that share dysregulation and aggregation of αSyn. The clinical manifestations of Lewy body disease include dementia with lewy bodies, Parkinson's disease and autonomic failure. Clinically, dementia with lewy bodies is characterized by progressive cognitive decline accompanied by core features: recurrent visual hallucinations, fluctuating attention and cognition, and motor features of parkinsonism. Suggestive features include neuroleptic sensitivity, changes in dopamine transporter single photon emission computerized tomography imaging and rapid eye movement sleep behavior disturbance. 8 CORTICOBASAL SYNDROME It is a rare syndrome with a progressive course, in most cases unresponsive to levodopa or other medication. At onset, Corticobasal syndrome typically presents with asymmetrical rigidity, bradykinesia and apraxia of the affected limbs, usually of the limb-kinetic type. 9 
LIMBIC ENCEPHALITIS
Limbic encephalitis (LE) is an autoimmune neuropsychiatric condition characterized by subacute cognitive symptoms, seizures and affective changes. Although LE is usually caused by an immune reaction secondary to neoplasms (mostly associated with lung or testicular cancer and in women with ovarian teratomas), different types of potentially treatable non-paraneoplastic limbic encephalitis (nPLE) have recently been described. The clinical features of LE are diverse, and early diagnosis of the disorder is frequently difficult. The cardinal sign of LE is a severe impairment of short-term memory or of episodic, anterograde memory. Anterograde amnesia is often associated with behavioral and psychological symptoms of dementia, such as anxiety, depression, irritability, personality change, acute confusional state, hallucinations and complex partial and secondary generalized seizures. The symptoms typically develop over a few weeks or months, but they may evolve over a few days (rapid progression). Examination of the cerebrospinal fluid (CSF) may show lymphocytic meningitis. 10 
HUNTINGTON DISEASE
It is an autosomal-dominant neurodegenerative disease caused by the expansion of a cytosine-adenine-guanosine trinucleotide (CAG) repeat within the HD gene, encoding an abnormally long polyglutamine moiety within the huntington protein that leads to marked atrophy of basal ganglia structures, the caudate and putamen, as well as less marked atrophy of other brain nuclei. Cognitive decline often accompanied by psychiatric symptoms is the other main sign of Huntington disease and can be present long before the first motor symptoms appear but can also remain mild in far-advanced stages of the disease. The hallmark of the illness is chorea, but some patients have little or no chorea and instead appear with parkinsonian features.
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PRION DISEASES
Prion diseases, also known as transmissible spongiform encephalopathies, are a group of fatal neurodegenerative disorders affecting humans and other mammalian species. The central event in transmissible spongiform encephalopathy pathogenesis is the conformational conversion of the cellular prion protein, PrP C , into the aggregate, β-sheet-rich, amyloidogenic form, PrP Sc .
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Sporadic Creutzfeldt Jakob Disease, the most common prion disease (85% of cases), has a prevalence estimated to be 0.5-1.5 cases per million; the mean age at onset is 65 years (range, 14-92 years), and the median and mean durations of illness are 4.5 and 8 months, respectively; only 4% of patients survive longer than 2 years. Diagnostic criteria for sporadic Creutzfeld-Jakob disease have been published based on the clinical signs of rapidly progressive dementia, with Myoclonus, a characteristic electroencephalograph (EEG) pattern, 14-3-3 protein in CSF and magnetic resonance imaging (MRI) findings.
CEREBRAL VASCULAR DISEASE
Cerebral white matter hyperintensities (WMHs), detected in vivo with MRI, are commonly used to assess cerebrovascular burden in cognitive impairment. However, the association between WMH and cognition is not consistent across the literature. A recent review examines evidence from published longitudinal studies, investigating the association of WMH with the following: (1) the risk of dementia in the general population; (2) the risk of conversion to dementia in the MCI population; and (3) cognitive decline in the general population. WMHs were associated with all types of dementia in the general population but not in MCI patients. Results are discrepant for global decline. WMHs appear to be early predictors of the risk of dementia, but this association appears to be modulated by cognitive reserve, age and the spatial distribution of lesions. There are, however, some limits in the use of WMH as a marker of vascular burden. In addition to their ischemic origin, WMHs may be the result of co-occurring morbidity. 13 Post-traumatic stress disorder and major depressive disorder frequently co-occur after traumatic experiences and share neurocognitive disturbances in verbal memory and executive functioning. 14 
DIAGNOSIS OF COGNITIVE DECLINE TODAY
Clinicians use neuropsychological tests, medical, neurological and psychiatric history, medical, neurological and psychiatric examination, and laboratory tests-routine hematological and biochemical examination, B12, folic acid, homocysteine levels, rapid plasma regain (for syphilis) and thyroid stimulating hormone. Also, sMRI is the preferred imaging tool, and Abeta, tau and phospho-tau are the CSF biomarkers that are widely used in clinical praxis, but only in research centers. EEG and event-related potentials are used only in some centers, but there is a trend to be used widely.
DIAGNOSIS OF COGNITIVE DECLINE IN FUTURE
Abeta and tau PET imaging, new biomarkers in CSF and blood samples are examinations that are used now in research to help in the diagnosis of dementia in preclinical stages.
Diagnosis of cognitive decline is mostly clinical and is aided by various scales.
Neuropsychological testing By testing multiple cognitive domains and avoiding ceiling effects, MCI can be identified before 60 years of age. Premorbid general cognitive ability is a risk/protective factor, but deficits after adjusting for early adult general cognitive ability suggest additional processes leading to declining trajectories. 15 There are several novel, potentially promising, approaches that are being explored for detecting early cognitive evidence of preclinical AD in presymptomatic individuals. 16 With normative cutoff values consortium to establish a registry for Alzheimer's disease total scores yielded 87-89% sensitivity and 84-86% specificity in screening for prodromal AD in a separate multinational population. The annual deterioration in all consortium to establish a registry for Alzheimer's disease compound scores was significant in the progressive (P ⩽ 0.001) but not in the stable MCI group (P40.08). Consortium to establish a registry for Alzheimer's disease total scores are a practical way of screening for prodromal AD and assessing cognitive progression in MCI. However, the new memory compound scores were more accurate compared with consortium to establish a registry for Alzheimer's disease subtests in predicting AD conversion. 17 There are many subjective and performance-based instrumental activities of daily living scales, some of which are useful in distinguishing between MCI and AD dementia and even between MCI and clinically normal elderly individuals. These scales have been associated with amyloid and neurodegeneration biomarkers of AD. Clinically normal elderly individuals who have a positive AD biomarker are thought to be at the preclinical stage of AD. 18 A big help in everyday clinical praxis, we have been using the Functional and Cognitive Assessment Scale (FUCAS) test since 2005. 19 In a recent study on 270 MCI, 402 AD patients and 108 healthy controls, behavioral assessment was performed by means of the Middelheim Frontality Score, Behavioral Pathology in AD Rating Scale, Cohen-Mansfield Agitation Inventory and the Cornell Scale for Depression in Dementia. Moderate-to-severe behavioral symptoms were present in 13% of MCI patients, as compared with 39% of AD patients and 3% of controls (P o 0.001). 20 Apathy is the most common neuropsychiatric symptom in MCI and AD dementia. A significant association was found between increased apathy (a lower Apathy Evaluation Scale score) and greater cortical PiB retention independent of age, but no significant association between apathy and regional fluorodeoxyglucose (FDG) metabolism. 21 Also, elevated CSF tau was found to be associated with psychosis in AD. 22 Routine laboratory exams. Blood and urine examination is necessary to exclude B 12 and folic acid deficiency, thyroid stimulating hormone abnormalities, homocysteinemia, anemia, electrolyte disturbances, renal or liver problems that can be responsible for cognitive decline and rapid plasma regain (for syphilis).
The availability of biomarkers does not replace or diminish the need for a thorough clinical evaluation. A structured clinical approach helps define the diagnosis and collects information essential for establishing a comprehensive care plan for patients with dementia and their families. The discovery of biomarkers, considered as surrogate markers of the underlying pathological changes, led an international work group to propose a new conceptual framework for AD in 2007 (Dubois et al. 23 ). According to the international work group, AD is now defined as a dual clinico-biological entity that can be recognized in vivo, prior to the onset of the dementia syndrome, on the basis of the following: (i) a specific core clinical phenotype comprising an amnestic syndrome of the hippocampal type and (ii) supportive evidence from biomarkers reflecting the location or the nature of Alzheimer-type changes. 24 After administration of a brief test of memory, MRI and CSF do not substantially affect the diagnostic accuracy for predicting progression to AD in patients with MCI. 25 Subjects with MCI who were clinically similar showed substantial heterogeneity in biomarkers. 26 Although the new criteria are proposed for research purposes, expert centers with adequate resources are encouraged to begin to use the proposed algorithm in order to move the field forward and facilitate translation into clinical practice.
ELECTROENCEPHALOGRAM EEG has a high sensitivity in separating AD patients from normal controls, and according to some researchers the sensitivity of EEG is higher than or equal to the best laboratory techniques (MRI, CT, single photon emission computerized tomography and PET). This is the reason why some clinicians recommend that all AD patients be studied at least once by EEG as well as by MRI. 27 There is a big correlation of EEG findings with other reliable biomarkers such as sMRI, even in MCI patients. Moretti et al. 28 in their recent study showed that MCI subjects with higher a3/a2 ratios when compared with subjects with lower and middle a3/a2 ratios showed minor atrophy in the ventral stream of the basal ganglia (head of the caudate nuclei and accumbens nuclei bilaterally) and of the pulvinar nuclei in the thalamus.
EVENT-RELATED POTENTIALS
Event-related potentials, in particular N200 and P300 waves, have been widely used over the last years in the study of AD and MCI. Both N200 and P300 latencies were found to be prolonged in MCI and AD patients compared with controls and were separately proposed as useful markers in the early AD diagnosis (Papaliagkas et al. 29 ). Recently, a new neurophysiological marker that incorporates changes in N200 and P300 latencies and amplitudes into a single parameter, roughly representing the voltage gradient in the latency window between N200 and P300, was suggested for the assessment of cognition changes in MCI patients (2011). Several studies have suggested the combination of event-related potentials waves with CSF proteins as an accurate diagnostic marker of MCI conversion to AD, which added to the diagnostic value of each marker separately.
In particular, CSF β-amyloid (1-42) levels, which are one of the most widely used AD biomarkers, when combined with N200 latency or P300 latency could discriminate AD converters from MCI patients with over 80% sensitivity and 89% specificity (Papaliagkas et al. 30, 31 ).
IMAGING BIOMARKERS
Within imaging markers (that is, amyloid imaging, 18 F-fluorodeoxyglucose [FDG]-PET, single photon emission computerized tomography and MRI), as well as how it is measured ("metric": visual, manual, semiautomated, or automated segmentation/ computation), the largest proportion of diagnostic LR+ and LR − variability was within 18 F-FDG-PET and MRI metrics, respectively. Diagnostic and prognostic accuracy of imaging AD biomarkers is at least as dependent on how the biomarker is measured as on the biomarker itself. 32 Structural Imaging Results demonstrate that cognitively normal individuals genetically determined to develop AD have a thinner cerebral cortex compared with noncarriers in regions known to be affected by typical late-onset sporadic AD. These findings provide further support for the hypothesis that cortical atrophy is present in preclinical AD 45 years prior to symptom onset. Further research is needed to determine whether this method could be used to characterize the age-dependent trajectory of cortical atrophy in Early detection of cognitive decline and dementia M Tsolaki presymptomatic stages of AD. 33 Greater baseline temporal and parietal atrophy is associated with worsening apathy and hallucinations in a large AD spectrum cohort. 34 Functional imaging Functional imaging studies help in early detection and are superior to biomarkers or structural MRI. Widespread disconnection was observed primarily in cortical hubs known to manifest early Alzheimer's disease pathology-namely, precuneus, parietal lobules, supramarginal and angular gyri and cuneus-with additional involvement of subcortical regions, sensorimotor cortex and insula. 35 A relationship between a subjective memory complaint composite score and cortical PiB binding was found to be significant, even after controlling for depressive symptoms. By contrast, there were no significant relationships between objective cognitive measures of memory and executive functions and cortical PiB binding. 36 Functional disruption of the default mode network occurs early in the course of autosomal-dominant AD, beginning before clinically evident symptoms and worsening with increased impairment. These findings suggest that default mode network functional connectivity magnetic resonance imaging scan may prove useful as a biomarker across a wide spectrum of diseases and support the feasibility of default mode network functional connectivity magnetic resonance imaging scan as a secondary end point in upcoming multicenter clinical trials in AD. 37 Quantitative results of four MRI and PET imaging metrics (fractional amplitude of low frequency fluctuation/default mode network, white matter lesion load, amyloid, and FDG rSUV values) found significant correlations between MRI metrics, including white matter lesion load/functional activity and PET amyloid load, which suggest the potential of MRI and PET-based biomarkers for early detection of AD. 38 Lower FDG-PET return on investment, values were associated with higher likelihood of conversion (p = 0.004), with the area under the curve yielding 82.0% (95% CI = (95.5%, 68.5%)). The Gray Matter volume return on investment, was not a significant predictor (p = 0.07). TMT-B but not the free recall tests was a significant predictor (area under the curve = 71% (95% CI = 50.4%, 91.7%)). For the combination of FDG-PET and TMT-B, the area under the curve was 93.4% (sensitivity = 82%, specificity = 93%). Voxel-based group comparison showed reduced FDG-PET metabolism within the temporo-parietal and prefrontal cortex in health controls converters. In conclusion, medial, temporal and parietal FDG-PET and executive function show a clinically acceptable accuracy for predicting clinical progression in elderly health controls subjects. 39 The clinical and research utility of amyloid imaging according to Laforce and Rabinovic comprises the following: (1) determine whether MCI is due to AD; (2) differentiate AD from non-AD dementia (for example, frontotemporal lobar degeneration), particularly in patients with early age at onset; (3) determine whether AD co-pathology is present in patients with cognitive impairment and other known neurologic disease (for example, Parkinson's disease, stroke/vascular disease, multiple sclerosis, epilepsy and HIV); (4) differentiate AD from nondegenerative cognitive decline (for example, depression, substance abuse); (5) determine whether AD is present in patients with advanced dementia and no reliable history; (6) identify whether AD is present in focal cortical syndromes (for example, posterior cortical atrophy, primary progressive aphasia, corticobasal syndrome); and (7) differentiate cerebral amyloid angiopathy from intracranial hemorrhage due to small-vessel vasculopathy. 40 A recent progress is a novel derivative for noninvasive imaging of tau pathology in AD. That means there are PET tracers that show the tau pathology, neurofibrillary tangles, in vivo. This new direction is very useful mostly in research for early diagnosis as well as for early treatment of the disease. 41 CSF MARKERS Baseline differences in CSF values-β-amyloid 1-42 (Aβ1-42), total tau (t-tau) and phosphorylated tau (p-tau)-were predictive of clinical symptoms that were a harbinger of a diagnosis of MCI 45 years before symptom onset and continue to show longitudinal changes as cognitive symptoms develop, demonstrating that baseline and longitudinal changes in CSF biomarkers are evident during the preclinical phase of AD. 42 However, abnormal ratios are noticed in health controls (31%), in subjective cognitive impairment (52%), in naMCI (68%) and in amnestic mild cognitive impairment patients (79%), according to the results of the DESCRIPA project. 43 The quantification of αSyn in CSF has been proposed as a diagnostic biomarker for Parkinson's disease and other αSyn-related diseases such as Multiple System Atrophy and dementia with Lewy bodies. Most studies show decreased levels of αSyn in diseased CSF samples compared with control samples, but discrepant findings and overlapping values have been a major limitation for the use of CSF αSyn as a biomarker. 44 BIOMARK-APD is a European-funded project that will harmonize the methods of CSF and blood biomarkers.
BLOOD MARKERS
In a recent unpublished study, we found an association of Clusterin with greater atrophy and a trend toward reduced regulated on activation, normal T cell expressed and secreted, neuron-specific enolase and transthyretin levels in the MCI group. 45 GENETICS Until 2009, we had only one risk gene for AD, APOE ε4, on chromosome 19. Now, 4 years after, we discuss about 22 risk genes for AD 46 and about 400 mutations in three chromosomes 21, 14 and 1. In cases suggestive for autosomal-dominant AD, a screening of PSEN1 mutation first is suggested, followed by APP and PSEN2 mutations on the basis of epidemiological data, but new specific biomarkers driving genetic screening are warranted. 47 
COMBINATION OF MARKERS
Memory impairment, still essential for the new revised research criteria in association with CSF or imaging biomarkers for the diagnosis of AD, is not always the prominent early deficit. Behavioral disturbances, epilepsy, myoclonus or Cerebral Amyloid Angiopathy (specific for APP mutations) may help in addressing diagnosis. However, structural or functional neuroimaging is more consistent with focal phenotypes than with the AD pathology. Thus, CSF or amyloid imaging may be useful in the differential diagnosis with other neurodegenerative dementias, especially in early-onset cases, but these biomarkers cannot be considered specific for the different involved genes.
For example, an in silico predicted missense variant in REST (rs3796529) was found exclusively in subjects with slow hippocampal volume loss and was validated using unbiased wholebrain analysis and meta-analysis across five independent cohorts. Cortical atrophy may be present in preclinical AD 45 years prior to symptom onset. 48 
PROGNOSIS OF COGNITIVE DECLINE
A recent study sought to determine the stability of the clinical etiologic diagnosis over time and to identify factors associated with instability. Lower diagnostic stability was significantly associated with older age, nonwhite race, milder disease at presentation, more underlying conditions contributing to cognitive decline, lack of a consistent spouse/partner informant and being evaluated by different clinicians on different visits. Multistate Markov modeling generally confirmed these associations. 49 Faster decline was evident in APOE ε4+ (a genetic risk factor for AD; n = 73) than in ε4-participants (n = 213), even after controlling for education, gender, ethnicity and baseline functional and cognitive abilities. This discrepancy increased with age, indicating an Age × Genotype interaction. 50 In conclusion, diagnostic criteria, medical and neurological examination, laboratory examinations for exclusion of reversible dementias and MRI are the clinical steps for the diagnosis and differential diagnosis of cognitive decline and dementia. All of the above-mentioned approaches are promising, although molecular imaging (PET) is currently a costly procedure available in relatively few centers, and lumbar puncture is moderately invasive. Furthermore, repeated measures are problematical in both cases. Blood (plasma) on the other hand is a more accessible bio-fluid suitable for repeated sampling, which is necessary in clinical trials. PET, blood and CSF biomarkers need more studies before being used in everyday clinical praxis.
